Literature DB >> 30546882

Distinct HLA class I and II genotypes and haplotypes are associated with multiple sclerosis in Bahrain.

Moudi Al-Nashmi1, Safa Taha1, Abdel Halim Salem2, Isa Alsharoqi3, Moiz Bakhiet1.   

Abstract

Multiple sclerosis (MS) has become prevalent in the Arabian Gulf area with high incidence in Bahrain due to environmental influences and genetic susceptibilities, but there is a lack of study into human leukocyte antigen (HLA) types in patients with MS in Bahrain. The present study aimed to study the HLA types expressed in MS patients compared with in control subjects. Blood samples from 50 Bahraini patients with MS and 50 Bahraini control subjects' were subjected to HLA tissue typing by polymerase chain reaction using sequence-specific primers. In comparison with those in control subjects, the allele frequencies of HLA class-I antigens A2, A9, A19, B5, B35 and B40 were higher in MS patients. For class II antigens, the allele frequencies of DR3, DR4 and DR16 were higher in MS patients. The allele frequency of DR15 was lower in MS patients than in control subjects but the difference was not statistically significant (P=0.138). The higher prevalence of the HLA-ABDR allele was common among the female patients with MS, in relapse remission stage, in cases with higher expanded disability status scale scores and with disease duration between 4 and 9 years. Haplotype HLA-A2-B40-DR2 exhibited significantly higher frequency in MS patients compared with in control subjects (P=0.03). In conclusion, the results indicated different alleles associated with MS compared with previous reviews. The present study supports the importance of identifying genetic susceptibilities and targets for therapies in specific populations and individuals, to personalize disease management in terms of prediction, protective measures and treatment.

Entities:  

Keywords:  alleles; expanded disability status scale; genes; human leukocyte antigen typing; multiple sclerosis; polymerase chain reaction

Year:  2018        PMID: 30546882      PMCID: PMC6256251          DOI: 10.3892/br.2018.1164

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  34 in total

1.  The HLA-DR13 haplotype is associated with "benign" multiple sclerosis in northeast Italy.

Authors:  P Perini; C Tagliaferri; M Belloni; G Biasi; P Gallo
Journal:  Neurology       Date:  2001-07-10       Impact factor: 9.910

2.  [Genetic risk factors for multiple sclerosis in the population of Altay].

Authors:  I V Smagina; S A El'chaninova; A G Zolovkina; Iu N Ignatova; E A Kudriavtseva
Journal:  Zh Nevrol Psikhiatr Im S S Korsakova       Date:  2011

3.  HLA B*44: protective effects in MS susceptibility and MRI outcome measures.

Authors:  B C Healy; M Liguori; D Tran; T Chitnis; B Glanz; C Wolfish; S Gauthier; G Buckle; M Houtchens; L Stazzone; S Khoury; R Hartzmann; M Fernandez-Vina; D A Hafler; H L Weiner; C R G Guttmann; P L De Jager
Journal:  Neurology       Date:  2010-08-17       Impact factor: 9.910

4.  Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.

Authors:  Kristen M Johnson; Huanxue Zhou; Feng Lin; John J Ko; Vivian Herrera
Journal:  J Manag Care Spec Pharm       Date:  2017-08

5.  HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility.

Authors:  Michael J Chao; Martin C N M Barnardo; Matthew R Lincoln; Sreeram V Ramagopalan; Blanca M Herrera; David A Dyment; Alexandre Montpetit; A Dessa Sadovnick; Julian C Knight; George C Ebers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-02       Impact factor: 11.205

6.  Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.

Authors:  Jenny Link; Malin Lundkvist Ryner; Katharina Fink; Christina Hermanrud; Izaura Lima; Boel Brynedal; Ingrid Kockum; Jan Hillert; Anna Fogdell-Hahn
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 7.  Multiple sclerosis-A disease on a dramatically rising trend in Iran: Review of possible reasons.

Authors:  Mohammad Ali Sahraian; Mohammad Sahebkar; Rouhullah Dehghani; Milad Derakhshan-Jazari; Vahid Kazami-Moghaddam; Ebrahim Kouchaki
Journal:  Iran J Neurol       Date:  2017-01-05

8.  Class II HLA interactions modulate genetic risk for multiple sclerosis.

Authors:  Loukas Moutsianas; Luke Jostins; Ashley H Beecham; Alexander T Dilthey; Dionysia K Xifara; Maria Ban; Tejas S Shah; Nikolaos A Patsopoulos; Lars Alfredsson; Carl A Anderson; Katherine E Attfield; Sergio E Baranzini; Jeffrey Barrett; Thomas M C Binder; David Booth; Dorothea Buck; Elisabeth G Celius; Chris Cotsapas; Sandra D'Alfonso; Calliope A Dendrou; Peter Donnelly; Bénédicte Dubois; Bertrand Fontaine; Lars Fugger; An Goris; Pierre-Antoine Gourraud; Christiane Graetz; Bernhard Hemmer; Jan Hillert; Ingrid Kockum; Stephen Leslie; Christina M Lill; Filippo Martinelli-Boneschi; Jorge R Oksenberg; Tomas Olsson; Annette Oturai; Janna Saarela; Helle Bach Søndergaard; Anne Spurkland; Bruce Taylor; Juliane Winkelmann; Frauke Zipp; Jonathan L Haines; Margaret A Pericak-Vance; Chris C A Spencer; Graeme Stewart; David A Hafler; Adrian J Ivinson; Hanne F Harbo; Stephen L Hauser; Philip L De Jager; Alastair Compston; Jacob L McCauley; Stephen Sawcer; Gil McVean
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

9.  Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis.

Authors:  Jenny Link; Ingrid Kockum; Aslaug R Lorentzen; Benedicte A Lie; Elisabeth G Celius; Helga Westerlind; Marie Schaffer; Lars Alfredsson; Tomas Olsson; Boel Brynedal; Hanne F Harbo; Jan Hillert
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

10.  Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects.

Authors:  Nikolaos A Patsopoulos; Lisa F Barcellos; Rogier Q Hintzen; Catherine Schaefer; Cornelia M van Duijn; Janelle A Noble; Towfique Raj; Pierre-Antoine Gourraud; Barbara E Stranger; Jorge Oksenberg; Tomas Olsson; Bruce V Taylor; Stephen Sawcer; David A Hafler; Mary Carrington; Philip L De Jager; Paul I W de Bakker
Journal:  PLoS Genet       Date:  2013-11-21       Impact factor: 5.917

View more
  3 in total

Review 1.  A review of possible therapies for multiple sclerosis.

Authors:  Hui Li; Gaojian Lian; Guang Wang; Qianmei Yin; Zehong Su
Journal:  Mol Cell Biochem       Date:  2021-04-22       Impact factor: 3.396

Review 2.  Major histocompatibility complex (MHC) associations with diseases in ethnic groups of the Arabian Peninsula.

Authors:  Halima Al Naqbi; Aurélie Mawart; Jawaher Alshamsi; Habiba Al Safar; Guan K Tay
Journal:  Immunogenetics       Date:  2021-02-02       Impact factor: 2.846

Review 3.  Association of infections with multiple sclerosis in Gulf Cooperation Council countries: a review.

Authors:  O Al Wutayd
Journal:  J Int Med Res       Date:  2019-12-27       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.